COVID-19 Research Study

Understanding the Impact of COVID-19 on OB/GYN Providers in the United States

Hypothesis:

The COVID-19 outbreak is affecting the practice of OB/GYN care and impacting the emotional and mental health of providers and their ability to care for patients.

Aims, purpose, or objectives:

1. Explore the experiences and concerns of OB/GYN physicians as represented by the Society Academic Specialists in General Obstetrics and Gynecology (SAGOG) members during the COVID-19 outbreak.
2. Survey the types of support services that are available to, and most desired by, OB/GYN physicians in the United States during the COVID-19 outbreak.

To participate:

https://redcap2.mayo.edu/redcap/surveys/?s=KNW3K8LWD7

Contact Information:

Enid Rivera-Chiauzzi, rivera-chiauzzi.enid@mayo.edu
Mayo Clinic

SASGOG is not involved in this study and has not reviewed its content.

Institutional IRB Exemption Letter

From: IRBe
Sent: Thursday, June 11, 2020 10:34
To: Rivera-Chiauzzi, Enid Y., M.D.
Subject: 20-004685 - A study has been deemed Exempt by the IRB

MAYO CLINIC

Principal Investigator Notification:

From: Mayo Clinic IRB
To: Enid Rivera-Chiauzzi
Re: **IRB Application #:** 20-004685
Title: Understanding the Impact of COVID-19 on OB/GYN Providers in the United States

IRBe Protocol Version: 0.01
IRBe Version Date: 5/20/2020 9:52 AM

IRB Approval Date: 6/11/2020
IRB Expiration Date:

The above referenced application was reviewed by expedited review procedures and is determined to be exempt from the requirement for IRB approval (45 CFR 46.104d, Category 2). Continued IRB review of this study is not required as it is currently written. However, any modifications to the study design or procedures must be submitted to the IRB to determine whether the study continues to be exempt.

The Reviewer noted that oral consent email is appropriate for this study. The oral consent email was reviewed and approved as written. As protected health information is not being requested from subjects, HIPAA authorization is not required in accordance with 45 CFR 160.103.

AS THE PRINCIPAL INVESTIGATOR OF THIS PROJECT, YOU ARE RESPONSIBLE FOR THE FOLLOWING RELATING TO THIS STUDY.
1) When applicable, use only IRB approved materials which are located under the documents tab of the IRBe workspace. Materials include consent forms, HIPAA, questionnaires, contact letters, advertisements, etc.
2) Submission to the IRB of any modifications to approved research along with any supporting documents for review and approval prior to initiation of the changes.
3) Submission to the IRB of all Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSO) and major protocol violations/deviations within 5 working days of becoming aware of the occurrence.
4) Compliance with applicable regulations for the protection of human subjects and with Mayo Clinic Institutional Policies.

Mayo Clinic Institutional Reviewer